EN 
FR 
Harness the Power of Real-World Evidence
Cytel’s robust real-world evidence (RWE) team harnesses global database access and unique analytical methods to transform real-world data into actionable insights for every stage of your drug development lifecycle.
RWE Insights and Innovation
Real-world evidence (RWE) is crucial for bridging the gap between clinical research and real-world applications, providing critical insights throughout the product lifecycle. Reliability of RWE is a crucial topic of debate and discussion among healthcare stakeholders and ensuring that high-quality and fit-for-purpose data is used is a primary challenge when conducting RWE studies. At Cytel, our RWE solutions integrate robust data collection, sophisticated analytics, and deep industry expertise to deliver actionable insights to enhance your decision-making and improve patient outcomes. Whether supporting your regulatory submissions, informing clinical strategy, or enhancing market access, Cytel’s RWE services are designed to provide a comprehensive understanding of treatments in actual practice settings, ensuring you can deliver effective and economically viable healthcare solutions.
Contact usGlobal database network
Access over 100 global databases for comprehensive insights into health information spanning billions of patient years.
Advanced analytical techniques
Utilize synthetic control arms and machine learning to create reliable and compelling evidence packages.
Expertise in regulatory compliance
Trusted by the US and EU regulators, our methodologies meet the highest standards for RWE studies.
Tailored RWE solutions
Customized strategies address your specific challenges across the drug development spectrum, from early research to post-market analysis.
Advanced Analytical Methods in RWE Studies
Our RWE studies employ advanced analytical methods including synthetic control arms, target trial emulation, transportability analyses, quantitative bias analyses, and machine learning, to provide you with comprehensive and strong evidence packages. Industry stakeholders, including regulators in the US and EU, endorse our innovative methodologies and we have published many studies and peer-reviewed articles that underscore our deep knowledge and expertise.
We offer a suite of RWE services tailored to meet the needs of today’s healthcare challenges.
Database Studies: The Backbone of RWE
Cytel’s database studies form the cornerstone of effective RWE, providing insights into epidemiology, treatment patterns, and healthcare resource utilization (HCRU). Our expertise extends to both retrospective and linked database studies, where we apply advanced statistical techniques to help you ensure robust, unbiased comparisons across treatments and patient groups. Our ability to handle large, diverse data sets allows for detailed post-approval safety studies and comparative effectiveness analyses, crucial for informing clinical practice and policy decisions.
Retrospective Database Studies:
Cytel leverages retrospective databases, such as claims data and electronic medical records (EMR), to perform in-depth analyses of epidemiology, treatment patterns, and healthcare resource utilization (HCRU). These studies utilize historical data to observe real-world outcomes over extended periods, enabling you to identify trends, efficacy, and potential areas for improvement in treatment protocols. Our application of high-dimensional propensity score matching and multivariable analysis techniques ensures that findings are robust and reflect real-world scenarios, providing invaluable insights for your healthcare decision-making.
Linked Database Studies:
Our linked database studies integrate data from multiple sources, such as medical charts, claims databases, and patient surveys, to give you a more comprehensive view of patient care and outcomes. This method enhances the depth and accuracy of the analysis by compensating for the limitations inherent in single-source data studies. Cytel uses both probabilistic and deterministic linkage methods to ensure the integrity and validity of the data, facilitating complex studies that require both clinical and non-clinical data inputs. These linked datasets are particularly valuable to help you validate treatment effectiveness and conduct post-authorization safety studies (PASS) that reflect the nuanced reality of medical practice.
Medical Chart Reviews: Deep Dives into Patient Data
Medical Chart Reviews (MCRs) offer you a precise examination of clinical and healthcare utilization patterns not available in standard databases. Our unique technical and legal infrastructure supports rapid, high-quality data collection across key markets, adhering to local regulatory standards. MCRs are instrumental for projects where you require specific, detailed information, such as mutation types, disease progression, and real-world treatment efficacy, providing an essential supplement to broader database studies.
Strategic Real-World Evidence: Driving Product Success
Strategic RWE at Cytel integrates sophisticated analytical techniques with comprehensive regulatory and market insights to optimize the development and commercialization of your pharmaceutical products. We can help you develop evidence generation plans, synthesize data through external control arms (ECA), and provide strategic consulting for HTA submissions and safety analyses. By aligning RWE studies with strategic objectives, we ensure that you can effectively demonstrate the value and safety of your products, facilitating better healthcare decisions and enhancing market access.
75+
Unique, global real-world data sources.
50+
RWE staff members within our 200-strong group of RWE & HEOR
100+
Drugs supported across 20+ therapeutic areas
Related Insights
Breaking Barriers in Rare Disease Research with Generative AI and Synthetic Data
External Control Arms: A Powerful Tool for Oncology and Rare Disease Research
Breathing Easier: How Wearables Are Revolutionizing Patient-Reported Outcomes in Respiratory Disease
Trustworthy AI in Action: Predicting Stroke Risk Transparently with Claims-Based Machine Learning
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug's probability of success and plot a clearer route to market.
